Drug intelligence / Profile preview

HRS-9813

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS-9813 is a small molecule autotaxin inhibitor being developed as an antifibrotic agent for the treatment of idiopathic pulmonary fibrosis (IPF). It is classified as a Class 1 innovative drug and has demonstrated efficacy in preclinical mouse models, significantly improving lung function and reducing pulmonary fibrosis with good safety. The drug is currently in Phase 1 clinical trials, primarily focused on evaluating its safety, tolerability, pharmacokinetics, and bioavailability in healthy volunteers. HRS-9813 was independently developed by Guangdong Hengrui Pharmaceutical[2][3][5][6].

Other names: HRS 9813HRS9813HRS-9813

Targets

ENPP2 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 2)

Beyond the preview

Go deeper on HRS-9813.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-9813.

Explore the full profile